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Pregnancy reprograms the epigenome of mammary
epithelial cells and blocks the development of
premalignant lesions
Mary J. Feigman1,5, Matthew A. Moss2,5, Chen Chen1,5, Samantha L. Cyrill1, Michael F. Ciccone1,
Marygrace C. Trousdell 1, Shih-Ting Yang1, Wesley D. Frey 3, John E. Wilkinson4 &
Camila O. dos Santos 1✉
Pregnancy causes a series of cellular and molecular changes in mammary epithelial cells
(MECs) of female adults. In addition, pregnancy can also modify the predisposition of rodent
and human MECs to initiate oncogenesis. Here, we investigate how pregnancy reprograms
enhancer chromatin in the mammary epithelium of mice and influences the transcriptional
output of the oncogenic transcription factor cMYC. We find that pregnancy induces an
expansion of the active cis-regulatory landscape of MECs, which influences the activation of
pregnancy-related programs during re-exposure to pregnancy hormones in vivo and in vitro.
Using inducible cMYC overexpression, we demonstrate that post-pregnancy MECs are
resistant to the downstream molecular programs induced by cMYC, a response that blunts
carcinoma initiation, but does not perturb the normal pregnancy-induced epigenomic land-
scape. cMYC overexpression drives post-pregnancy MECs into a senescence-like state, and
perturbations of this state increase malignant phenotypic changes. Taken together, our
findings provide further insight into the cell-autonomous signals in post-pregnancy MECs
that underpin the regulation of gene expression, cellular activation, and resistance to
malignant development.
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In mammals, the physiological stimulus brought by preg-nancy results in considerable developmental reorganiza-tion, with mammary glands playing pivotal role in milk
production and offspring nourishment. Substantial tissue
remodeling, including the expansion of epithelial cells and
ductal structures, is followed by the accumulation of milk
droplets as gestation progresses. During lactation, milk pro-
duction is synchronized with milk release by a series of
transcriptional and mechanical events in luminal and myoe-
pithelial cells. As lactation ceases, the mammary gland returns
to a nonsecretory state and adopts a tissue organization that
resembles the prepregnancy one1.
However, post-pregnancy mammary epithelial cells (MECs)
are distinct from their pre-pregnancy counterparts, with tran-
scriptional networks being differentially regulated in post-
pregnancy mammary tissue from mice/rodents and humans2–6.
Several reports have also suggested that post-pregnancy mam-
mary glands from several mammalian species respond robustly to
the signals of consecutive pregnancies7–10, suggesting a molecular
memory of prior pregnancies. In fact, whole-genome bisulfite
sequencing has revealed that pregnancy induces stable and spe-
cific changes to DNA methylation in MECs11,12. These epigenetic
alterations correlated with the enhanced kinetics of gene reacti-
vation in a subsequent pregnancy, and suggest that loss of DNA
methylation may underlie epigenetic memory in the post-
pregnancy mammary gland12.
Pregnancy signals exert functions in the MECs that go beyond
the primary function of milk production and secretion, and
include modifying the risk of breast cancer in rodents and
humans. While there is an increase in breast cancer risk for
roughly 5–10 years after parturition13–15, there is a long-term
reduction of breast cancer risk for women completing a full-term
pregnancy before the age of 3016–19. In several rodent systems,
the inhibition of carcinogen-induced and genetic-induced mam-
mary tumorigenesis has also been reported post pregnancy or
upon pre treatment with pregnancy hormones17,20–22. Given the
stability of the molecular programs instated by pregnancy in
MECs, and the longevity of cancer preventive effects in rodents
and humans, it is likely that these protective effects have a
nongenetic basis.
To evaluate this hypothesis, we characterized the dynamics of
gene reactivation and enhancer organization in murine MECs as
they respond to pregnancy signals or early oncogenesis. Analyses
of the active enhancer landscape (using H3K27ac ChIP-seq),
revealed stable epigenomic alterations that influence the tran-
scriptional output of post-pregnancy MECs in response to preg-
nancy signals in fat-pad transplantation assays and in organoid
systems.
To characterize the influence of a pregnancy-induced epi-
genome on the response to oncogene expression, we used a
transgenic mouse strain (CAGMYC), in which overexpression
of the oncogene cMYC, an inducer of mammary tumor devel-
opment23, is driven in a doxycycline (DOX)-dependent man-
ner. Post-pregnancy MECs did not undergo malignant
transformation in response to cMYC overexpression under
in vivo or in vitro conditions, in marked contrast to pre-
pregnancy MECs, which engaged in abnormal, carcinoma-like
growth. Transcriptomic and epigenetic analysis illustrated that
cMYC overexpression drives post-pregnancy MECs into a
senescence-like state, and perturbations to such state increased
malignant phenotypic changes. Overall, our studies provided
new insights into the role for pregnancy in altering epigenomic
landscapes and in suppressing the malignant transformation of
MECs, and suggest that the influence of pregnancy on breast
cancer risk can occur, at least in part, via epigenomic
reprogramming.
Results
Characterization of the pregnancy-induced mammary epigen-
ome. Our previous observation that pregnancy induces loss of
DNA methylation at specific genomic regions in post-pregnancy
MECs suggests that such regions assume an active regulatory state
after pregnancy12. To test this hypothesis, we mapped global gene
expression (RNA-seq) of FACS-isolated luminal MECs from
nulliparous (pre-pregnancy) and parous (post-pregnancy=
21 days of gestation, 20 days of lactation, 60 days of post-lactation
involution) Balb/c female mice, as well as MECs harvested from
female mice during exposure to pregnancy hormones (EPH). For
the first and second EPH time points, nulliparous or parous
female mice, were treated with slow-released estrogen and pro-
gesterone hormones for short-term exposure (6 and 12 days)
(Supplementary Fig. 1a). This procedure ensures precise timing of
pregnancy-hormone exposure in nulliparous and parous female
mice, and promotes mammary histological and epigenetic mod-
ifications that closely resemble those in mice exposed to preg-
nancy hormones following conception12,24.
Unsupervised, global gene expression analysis of pre- and post-
pregnancy luminal MECs demonstrated overall similar transcrip-
tional programs, suggesting that a pregnancy cycle does not alter
epithelial identity during tissue homeostasis (Fig. 1a, b). Focused
analysis of genes correlated with MEC parity status25 confirmed
the upregulation of 38% of the parity-induced genes in post-
pregnancy luminal MECs (Supplementary Fig. 1b). Luminal
MECs harvested during the early stages of a second EPH (D6)
clustered together with those harvested at a later time-point
during the first EPH (D12), suggesting that post-pregnancy MECs
activate pregnancy-induced transcription earlier in response to
re-exposure to pregnancy signals (Fig. 1a, b).
To determine whether this response to re-exposure to
pregnancy signals was linked to epigenetic changes, we profiled
the active histone mark H3K27ac in the same cohort of luminal
MECs subjected to RNA-seq. Total peak analysis revealed that
pregnancy substantially expanded the active regulatory landscape
of luminal MECs, with post-pregnancy MECs displaying an
approximately 10-fold increase in H3K27ac peaks (n= 207,585),
in contrast to pre-pregnant MECs (n= 19,985) (Fig. 1c).
Regulatory regions exclusive to post-pregnancy MECs showed a
38-fold gain of H3K27ac peaks at genic regions (n= 145,917),
and a 53-fold gain at intergenic regions (n= 45,174), over the
same regions in pre-pregnancy MECs, suggesting that pregnancy-
induced changes may expand the MEC enhancer landscape
(Supplementary Fig. 1c). Gene ontology analysis (GO terms)
demonstrated that pre-pregnancy H3K27ac exclusive regions
were located near genes encoding protein functions associated
with myeloid differentiation, cell–cell junction, and epithelial cell
morphogenesis, while H3K27ac peaks exclusive to post-
pregnancy MECs were enriched for pathways involved in
regulation of histone H3-K27 methylation, transcription in
response to UV-induced DNA damage, and regulation of
gluconeogenesis (Supplementary Fig. 1d, e). These observations
suggest that pre- and post-pregnancy MECs may regulate distinct
molecular pathways during mammary tissue homeostasi. The
H3K27ac landscape changes were also detected in luminal MECs
during pregnancy, indicating that pregnancy signals are key
inducers of these enhancer changes, which our analysis suggests
are stably maintained in subsequent pregnancies (Fig. 1d and
Supplementary Fig. 1f)
To identify the relationship between post-pregnancy H3K27ac
peaks and their role in enhancer-mediated gene regulation, we
used the ROSE algorithm to combine nearby peaks located at
genic and intergenic regions and to delineate candidate
enhancers/super enhancer regions. H3K27ac peaks exclusive to
pre-pregnancy MECs define ~5000 enhancers/super enhancers, in
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contrast to ~60,000 enhancers/super enhancer defined by
H3K27ac peaks exclusive to post-pregnancy MECs (parity-
induced elements, PIEs), consistent with pregnancy expanding
the active enhancer landscape (Supplementary Fig. 1g). Further
analysis demonstrated that most PIEs have the H3K27ac mark in
MECs harvested from both first and second EPH (n= 2263),
however more PIEs (2-fold) were active only during the second
EPH, suggesting that such elements play a role during re-
exposure to pregnancy hormones (Supplementary Fig. 1h).
In addition, we identified ~15 K genes associated with PIEs,
which we used to understand the effects of EPH and gene
reactivation of luminal MECs. Over 600 PIE-associated genes
were upregulated 16-fold or higher in luminal MECs harvested
from mice during a second EPH (Log2FoldChange > 4, red box),
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in comparison with those cells harvested from mice exposed
during first EPH (Fig. 1e). These upregulated PIE genes were
enriched for functions involved in milk production26, thus
supporting that the pregnancy-induced enhancer landscape
associates with activation of pregnancy-related programs in
response to re-exposure to pregnancy hormones.
Our analyses of total luminal MECs do not exclude the
possibility that less differentiated mammary stem cells (MaSCs)
and progenitor cells could be involved in the epigenetic memory
of pregnancy. Transitions during pregnancy cycles could also
result in alterations to the mammary microenvironment,
involving cell autonomous and non-autonomous regulatory cues
to sustain MECs response to consecutive pregnancy signals. To
dissect the microenvironment’s role in post-pregnancy MEC
response to pregnancy hormones, we used mammary fat-pad
transplantation assays. Cleared fat-pads from pre-pubescent,
virgin female mice were transplanted with either pre- or post-
pregnancy CD1d+ MaSCs, which have increased mammary
reconstitution activity in fat-pad transplants27. Recipient female
mice (2-month post transplantation) were exposed to pregnancy
hormones for 6 days, followed by histological analysis of their
mammary glands (Supplementary Fig. 2a). Dissociated and flow
cytometer analyzed mammary tissue transplanted with either pre-
or post-pregnancy MaSCs showed comparable ratios of luminal
and myoepithelial cells after tissue engraftment, suggesting that
pregnancy did not affect lineage commitment and differentiation
in transplanted MECs (Supplementary Fig. 2b). Histology of
transplanted glands from mice during EPH demonstrated that
transplantation of post-pregnancy CD1d+ MaSCs yielded a 1.4-
fold greater increase in ductal structures (668 ± 32) than glands
transplanted with pre-pregnancy CD1d+ MaSCs (467 ± 18),
suggesting that post-pregnancy MECs retain their ability to react
more robustly to pregnancy signals even after fat-pad transplan-
tation (Fig. 1f, g).
Enhanced branching morphogenesis in response to re-
exposure to pregnancy hormones was also recapitulated in
in vitro cultures of murine mammary organoids. Post-pregnancy
mammary organoids cultured with estrogen, progesterone, and
prolactin hormones (complete medium) displayed a 2.3-fold
greater number of branching organoids compared with pre-
pregnancy cultures (Fig. 1h, i). Furthermore, additional analysis
demonstrated increased Csn2 mRNA levels (10-fold) and
increased CSN2 protein levels (approximately 4-fold), in post-
pregnancy organoids cultured with pregnancy hormones com-
pared with pre-pregnancy organoids grown under the same
hormone conditions (Fig. 1j, Supplementary Fig. 2c–d, and
Supplementary Table 1). Given that Csn2 was amongst the genes
elevated during second EPH (Fig. 1e), our results support that
cell-autonomous signals control phenotypic and molecular
alterations in response to re-exposure pregnancy hormones.
cMYC overexpression and mammary premalignant lesion
development. Pregnancy decreases mammary tumor frequency
in mouse models of mammary oncogenesis17,20–22. Several of
these studies utilized mammary gland-specific promoters, such as
MMTV and WAP-CRE, to drive oncogene expression and tumor
development. However, these promoters are enhanced by signals
present during pregnancy and lactation28–30, thus potentially
masking epigenomic and transcriptomic changes associated with
early oncogenesis and pregnancy-induced protection. To over-
come this problem, we utilized a mouse model overexpressing
cMYC using the CAG promoter, which is independent of preg-
nancy/lactation signals, under the control of DOX (CAGMYC,
Supplementary Fig. 3a).
Nulliparous CAGMYC female mice died after greater than
8 days of DOX treatment, consistent with prolonged cMYC
overexpression being deleterious to animal health31. Thus, to
investigate cMYC-driven oncogenesis in live, healthy animals, we
analyzed mammary glands from CAGMYC female mice after 2
(DD2) or 5 days (DD5) of DOX treatment. DOX treatment
induced substantial histo-pathological alteration to the mammary
gland, including flattening of ductal structures and moderate
(DD2) to severe, diffuse (DD5) epithelial hyperplasia with atypia,
alterations frequently observed in premalignant mammary lesions
in mice32 (Fig. 2a, right panels). None of these alterations were
seen in the control CAG-only transgenic mice (Fig. 2a, left panel).
Analysis of cytokeratin composition in CAGMYC female mice
revealed a progressive expansion of cytokeratin 8 (KRT8)
expressing cells, a hallmark of luminal-like cells33, over the
course of the DOX treatment (Fig. 2b). This phenotype was
accompanied by the progressive thinning of the basal-like cells
(cytokeratin 5, KRT5), often observed during mammary tissue
hyperplasia (Fig. 2b).
Given that cMYC-driven mammary tumors may show
pathological and transcriptional heterogeneity, we asked which
transcriptomic alterations were induced by cMYC overexpression
in during the establishment of premalignant lesions. Total
CAGMYC MECs were isolated from nulliparous mice during
sustained cMYC overexpression (DD2 and DD5) and analyzed
using RNA-seq. In DD2 MECs, we observed enrichment for
pathways involving cellular metabolism, such as mitochondrial
function and gene splicing, in contrast to pathways upregulated in
DD5 MECs, which are associated with control of cell commu-
nication processes (Fig. 2c). These results suggest a progressive
alteration of transcriptional programs by cMYC overexpression,
which associates with the initial stages of oncogenesis in
Fig. 1 Characterization of the pregnancy-induced mammary epigenome. a Heatmap distribution of gene expression data collected from FACS-isolated
luminal MECs harvested from female mice at several developmental stages. b Principal component analysis of gene expression datasets from FACS-
isolated luminal MECs harvested from female mice at several developmental stages. c Venn diagram demonstrating the number of shared and exclusive
H3K27ac ChIP-seq peaks of FACS-isolated MECs from pre-pregnancy female mice (blue circle) and post-pregnancy female mice (orange circle).
d Genome browser tracks showing distribution of H3K27ac peaks at distinct pregnancy cycles for Frzb locus. e Expression of genes associated with parity-
induced elements (PIEs), according to Log2FoldChange (differential expression) in luminal MECs harvested from female mice during first and second
exposure to pregnancy hormones (EPH). Boxes indicate genes upregulated during second exposure to pregnancy hormones (Log2FoldChange > 2, red).
f, g H&E-stained histology images and duct quantification from mammary glands transplanted with pre-pregnancy CD1d+ MaSCs (f, left panel) or post-
pregnancy CD1d+MaSCs (g, right panel), harvested on day 6 of pregnancy-hormone exposure (EPH). n= 3 mammary glands injected with pre-pregnancy
CD1d+ MaSCs, and n= 3 mammary glands injected with post-pregnancy CD1d+ MaSCs. *p= 0.04. Scale: 200 µm. h, i Representative images and
branching quantification of mammary organoid culture derived from pre- and post-pregnancy MECs (Balb/C mice), grown with either essential media or
complete media (containing estrogen (E2), progesterone (P4), and prolactin (Prol). n= 3 independent biological replicates. *p= 0.02 and **p= 0.003.
Scale: 200 µm. j Immunofluorescence images of mammary organoid culture derived from pre- and post-pregnancy MECs, grown with either essential
media or complete media, visualizing, KRT8 (blue), KRT5 (red), and CSN2 (green). Scale: 100 µm. For all analysis, error bars indicate standard error of
mean across samples of same experimental group. p values were defined using Student t test.
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Fig. 2 cMYC overexpression and mammary premalignant lesion development. a H&E-stained mammary gland images from nulliparous CAG only and
CAGMYC female mice, with no DOX treatment (ND) and treated with DOX for 2 days (DD2) and for 5 days (DD5). Scale: 200 µm. b Immunofluorescence
images of mammary glands from nulliparous CAGMYC female mice, with no DOX treatment (ND), and treated with DOX for 2 (DD2) and 5 days (DD5),
visualizing DAPI (blue), KRT8 (green), KRT5 (magenta), and cMYC (yellow). Scale: 100 µm. c GSEA analysis of transcriptional programs enriched in
CAGMYC total MECs harvested from nulliparous female mice treated with DOX for 2 days (DD2) and for 5 days (DD5). NES normalized enrichment
score. d Principal component analysis of gene expression levels from CAGMYC total MECs harvested from nulliparous female mice treated with DOX,
compared with publicly available gene expression datasets generated using tumor tissue from transgenic mouse models of mammary tumorigenesis.
e Immunofluorescence images of mammary glands from nulliparous CAGMYC female mice treated with DOX for 5 days (DD5), visualizing DAPI (blue),
ERα (magenta), and cMYC (yellow). Scale: 200 µm. f Density plot showing H3K27ac peak intensity at computationally defined e-box DNA binding motifs
in MECs harvested from CAGMYC nulliparous female treated with DOX for 2 days (DD2) and 5 days (DD5). g Genome browser tracks showing
distribution of H3K27ac peaks for Tbx3 and Repp5 genomic loci in WT and DD2 CAGMYC MECs.
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mammary glands. We also utilized a transcriptomic approach to
classify CAGMYC premalignant lesions according to those from
classical models of mammary oncogenesis34. We found that the
transcriptional profiles of CAGMYC MECs clustered closely with
those from luminal-like mammary tumors, including MMTV-
PyMT and MMTV-Myc models (Fig. 2d and Supplementary
Fig. 3b). Tissue staining with antibodies against estrogen receptor
alpha (ERα), a marker for common luminal-like tumor subtypes,
demonstrated that CAGMYC MECcomprised malignant lesions
with positive ERα receptor nuclear staining, supporting their
luminal-like classification (Fig. 2e and Supplementary Fig. 3c).
To investigate the effects of short-term cMYC overexpression
on the epigenome of MECs we mapped the active enhancer
landscape (H3K27ac ChIP-seq) of total CAGMYC MECs. Many
of the H3K27ac peaks present in DD5 CAGMYC MECs (96%)
were also present in DD2 CAGMYC MECs, suggesting that
development of premalignant mammary lesions largely rely on
programs activated during the initial response to cMYC over-
expression (Supplementary Fig. 3d, e).
cMYC deletion in mice impaired ductal alveolar genesis during
pubescence and pregnancy, indicating its requirement for normal
mammary gland development35. Thus, we asked whether cMYC
overexpression activated a defined set of regulatory regions in
MECs undergoing premalignant development. We focused on the
gain of H3K27ac at genomic regions recognized by cMYC (e-
boxes)36 in response to cMYC overexpression. Roughly, 4500
H3K27ac peaks were detected at e-boxes in wild-type (WT), non-
transgenic MECs and in CAGMYC MECs, suggesting that a set of
cis-regulatory elements are activated in MECs independently of
cMYC overexpression (Supplementary Fig. 3f). In contrast, we
detected a defined set of e-boxes that gained H3K27ac peak
intensity in response to cMYC overexpression (Fig. 2f). Genome
browser tracks illustrate increased H3K27ac levels in MECs after
induction of cMYC overexpression, at cMYC downstream targets
Tbx3 and Reep5, both of which have been implicated in
mammary oncogenesis37,38 (Fig. 2g). Thus, short-term cMYC
overexpression activates specific epigenomic and transcriptional
networks, and causes alterations to tissue morphology resembling
those of murine mammary oncogenesis.
The effects of cMYC overexpression on post-pregnancy MECs.
To investigate the effects of cMYC overexpression on post-
pregnancy MECs, we treated parous CAGMYC female mice with
DOX for 5 days (Supplementary Fig. 4a). Histological analysis
revealed that mammary glands of nulliparous female mice dis-
played a ductal content 3-fold higher than mammary glands from
parous CAGMYC female mice, which remained largely unaf-
fected by cMYC overexpression (Fig. 3a, b). In agreement,
mammary glands from parous CAGMYC female mice showed
tissue morphology and duct numbers (276 ± 42) similar to those
from the DOX-treated, CAG-only control group (382 ± 4), sup-
porting that post-pregnancy mammary glands retained a mostly
normal phenotype in response to cMYC overexpression (Sup-
plementary Fig. 4b, c). These phenotypic differences were not
caused by inefficient transgene induction, as pre- and post-
pregnancy CAGMYC MECs expressed comparable cMYC mRNA
and protein levels (Fig. 3c and Supplementary Fig. 4d).
To explore whether the resistance to premalignant lesion
development was driven by cell-autonomous or non-autonomous
mechanisms, we transplanted pre- and post-pregnancy CAG-
MYC CD1d+ MaSCs into the fat-pads of nulliparous, CAG-only
female mice, followed by DOX treatment (Supplementary Fig. 4e).
In response to cMYC overexpression, mammary fat-pads
transplanted with pre-pregnancy CAGMYC MECs demonstrated
severe complex epithelial hyperplasia with atypia and abnormal
ductal morphology, in contrast to fat-pads transplanted with
post-pregnancy CAGMYC MECs, which displayed mostly
normal tissue histology and lacked abnormal ductal structures
(Fig. 3d, e). There were no significant differences on the total
number of ducts, or cMYC protein levels, in glands transplanted
with either pre-pregnancy (217 ± 49 ducts) or post-pregnancy
(140 ± 9 ducts) CAGMYC MECs, suggesting that the lack of
abnormal ductal clusters in the post-pregnancy condition was not
an artifact associated with transplantation of cMYC overexpres-
sing cells (Fig. 3e, f). Extending cMYC overexpression to 30 days
(DD30) also failed to induce the development of premalignant
lesions in mammary glands transplanted with post-pregnancy
CAGMYC CD1d+ MaSCs, in contrast to glands transplanted
with pre-pregnancy CAGMYC CD1d+MaSCs, which progressed
from epithelial hyperplasia to undifferentiated carcinoma lesions
(Fig. 3g). Collectively, these results are consistent with cMYC
overexpression being less efficient at driving malignant transfor-
mation of post-pregnancy MECs.
To investigate whether the cell-autonomous, hyperplasia-
reduced phenotype of post-pregnancy CAGMYC MECs would
persist under in vitro growth conditions, we utilized mammary
organoid cultures. Analysis of pre- and post-pregnancy CAG-
MYC organoid cultures exposed to increasing concentrations of
DOX demonstrated similar induction of cMYC protein levels
(Supplementary Fig. 4f, g). Morphological analysis of untreated
organoid cultures revealed that pre- and post-pregnancy
CAGMYC organoid cultures displayed similar morphology, with
pre-pregnancy organoids displaying a higher incidence of normal
branching (39 organoids, 35% of total organoids) than post-
pregnancy organoids (10 organoids, 8% of total organoids),
possibly due to differences on cell culture adaptation (Fig. 3h—
left panel, Supplementary Fig. 4h).
DOX treatment of the organoid cultures resulted in abnormal
branching of pre-pregnancy CAGMYC organoids, marked by
increased cell density in the center of the organoids, a phenotype
7.9-fold (DD1) and 3.1-fold (DD2) reduced in post-pregnancy
CAGMYC organoids (Fig. 3h, i). Pre-pregnancy CAGMYC
organoids were also 2.9-fold larger than post-pregnancy CAG-
MYC organoids (Fig. 3j), further supporting that cell-
autonomous signals present in post-pregnancy CAGMYC MECs
impact the development of premalignant phenotypes in response
to cMYC overexpression.
Post-pregnancy MECs have limited response to cMYC over-
expression. To define the transcriptional output of post-
pregnancy MECs in response to cMYC overexpression, we car-
ried out unsupervised gene expression analysis on DOX-treated,
pre- and post-pregnancy CAGMYC MECs (Supplementary
Fig. 5a). cMYC overexpression did not alter lineage-specific
transcription, as post-pregnancy luminal and myoepithelial cells
clustered together with their pre-pregnancy counterparts
(Fig. 4a). Analysis of the parity-associated factors (Supplementary
Fig. 1b) showed that 19% and 23% of these gene signatures
remain upregulated in post-pregnancy luminal and myoepithelial
CAGMYC MECs, respectively, suggesting that pregnancy-
associated transcription signatures are not substantially altered
by cMYC overexpression (Supplementary Fig. 5b, c).
Unbiased differential gene expression analysis demonstrated
downregulation cMYC target genes, and genes associated with
responses to estrogen in post-pregnancy CAGMYC MECs
(Fig. 4b). Comparing gene expression levels of cMYC-associated
genes in CAGMYC luminal MECs with those in WT, non-
transgenic luminal MECs, revealed increased levels of mRNA in
both pre- and post-pregnancy CAGMYC MECs (Log2Fold-
Change >1), demonstrating that cMYC overexpression was
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induced successfully in both conditions (Supplementary Fig. 5d,
left panel). However, the levels of cMYC-induced gene expression
were approximately 2-fold higher in pre-pregnancy CAGMYC
MECs, relative to post-pregnancy CAGMYC MECs (Supplemen-
tary Fig. 5d), supporting that cMYC overexpression is less
efficient at activating transcriptional programs in MECs that have
been exposed to a full pregnancy cycle.
We next compared the effects of cMYC overexpression on the
active (H3K27ac) regulatory landscape of total pre- and post-
pregnancy CAGMYC MECs. cMYC overexpression induced a 6-
fold increase in H3K27ac signal intensity at promoter regions in
pre-pregnancy CAGMYC MECs, compared with promoter
regions from pre-pregnancy WT MECs (Fig. 4c). Conversely,
the effect of cMYC overexpression on promoter regions was not
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as strong in post-pregnancy CAGMYC MECs, which displayed 3-
fold less H3K27ac signal intensity compared with those of pre-
pregnancy CAGMYC MECs (Fig. 4c). This differential response
to cMYC overexpression was also reflected on the total number of
detected H3K27ac peaks, with 26% (n= 890) mapping to
promoter regions in pre-pregnancy, compared with 6% (n=
295) of promoter regions in post-pregnancy CAGMYC MECs
(Supplementary Fig. 5e). Conversely, a larger percentage of
H3K27ac peaks from post-pregnancy CAGMYC MECs mapped
to genic regions (80%), compared with pre-pregnancy CAGMYC
MECs (60%), consistent with pregnancy-induced expansion of
putative cis-regulatory regions in MECs (Fig. 1), which was not
significantly altered by cMYC overexpression (Supplementary
Fig. 5e). Analysis of H3K27ac intensity levels at PIEs demon-
strated retained, parity-induced high H3K27ac levels in post-
pregnancy CAGMYCMECs, indicating cMYC overexpression did
not perturb pregnancy-induced epigenomics signatures (Fig. 4d).
We next asked whether H3K27ac signals would be differen-
tially enriched at e-box DNA motifs in pre- and post-pregnancy
CAGMYC MECs. Post-pregnancy CAGMYC MECs displayed
weaker H3K27ac peak intensity at e-boxes (~4000 regions) in
response to cMYC overexpression compared with pre-pregnancy
CAGMYC MECs (Supplementary Fig. 5f). In agreement,
chromatin accessibility analysis (ATAC-seq) demonstrated a
decrease in accessible chromatin at e-box regions in post-
pregnancy CAGMYC MECs (Fig. 4e). Additional chromatin
accessibility analysis identified a discrete number of enhancer
regions exclusive to post-pregnancy CAGMYC MECs (n= 3248
ATAC-seq peaks), which were associated with biological
processes controlled by pregnancy signals (Supplementary Fig. 5g,
h), further supporting that post-pregnancy CAGMYC MECs
transcriptome and epigenome are not substantially altered by
cMYC overexpression.
In order to compare changes in H3K27ac levels with cMYC
DNA occupancy we analyzed the Epha2 gene, which codes for a
tyrosine receptor kinase expressed in mammary tumors39, and
found it to display decreased H3K27ac intensity in response to
cMYC overexpression in post-pregnancy CAGMYC MECs
(Supplementary Fig. 6a). ChIP-qPCR of Epha2 and Tbx3 genes
(Supplementary Fig. 3f) revealed a approximately 3-fold higher
cMYC DNA occupancy in pre-pregnancy CAGMYC MECs,
further supporting that cMYC is less efficient at associating
with chromatin at these genomic regions in post-pregnancy
CAGMYC MECs (Supplementary Table 2 and Supplementary
Fig. 6b, c).
To analyze the genome-wide distribution of cMYC-chromatin
occupancy in pre- and post-pregnancy CAGMYC MECs, we
utilized Cleavage Under Targets and Release using Nuclease
(Cut&Run). Unbiased transcription factor (TF) DNA-motif
analysis revealed enrichment of e-box motifs within the
chromatin peaks co-immunoprecipitated with cMYC, suggesting
concordance between the observed regions of cMYC-chromatin
occupancy (cMYC peaks), and DNA motifs recognized by cMYC
(Supplementary Table 3). Differential Cut&Run peak analysis
revealed an approximately 3-fold reduction in cMYC peaks in
post-pregnancy CAGMYC MECs (n= 337 regions), compared
with those found in pre-pregnancy CAGMYC MECs (n= 1127
regions), supporting that cMYC overexpression is less efficient in
altering the epigenome of post-pregnancy CAGMYC MECs
(Fig. 4f). GO term analysis of cMYC peaks enriched in
prepregnancy CAGMYC MECs demonstrated association with
pathways that regulate insulin receptor activity, a process
regulated by cMYC during cellular malignant transformation40
(Supplementary Fig. 6d). cMYC peaks enriched in post-
pregnancy CAGMYC MECs were associated with genes that
promote decreased tumorigenesis and autophagy41 (Supplemen-
tary Fig. 6e, f and Fig. 4g). Expression analysis of genes associated
with autophagy and senescence, a byproduct of autophagy
processes42, confirmed their upregulation in post-pregnancy
CAGMYC MECs (Supplementary Fig. 6g, h). Specifically, we
found increased mRNA levels of the tumor suppressor gene
Ecrg4, a factor downregulated in breast cancer tissue43, in post-
pregnancy CAGMYC MECs (~6 Log2FoldChange), and down-
regulation of Bcl2L12 and Tbx3 mRNAs, factors whose low
expression has been correlated with a senescence-like state44,45.
Further analysis to define whether cMYC overexpression
results in a senescence-like phenotype, demonstrated that DOX-
treated, post-pregnancy CAGMYC organoids express decreased
levels of STAT3 protein, downregulation of which induces
premature senescence46, and increased levels of p53 protein, a
master regulator of senescence47 (Supplementary Fig. 6i). We also
detected decreased levels of p300 and acetyl p300 proteins
specifically in organoids derived from post-pregnancy CAGMYC
MECs, a histone acetyltransferase responsible for H3K27ac
catalysis, and expressed at low levels in senescent cells48,
indicating that parity may sensitize MECs to a cMYC-induced
pre-senescence state (Fig. 4h).
Pregnancy-induced expansion of the H3K27ac landscape
controls tissue development in response to pregnancy signals,
and could also play a role in regulating autophagy and
senescence, therefore interfering with cMYC overexpression-
driven phenotypes associated with malignant transformation of
MECs. Moreover, it was recently shown that knockdown of
residual p300 levels in senescent cells suppressed the expression
Fig. 3 The effects of cMYC overexpression on post-pregnancy MECs. a, b H&E-stained images and duct quantification from mammary glands harvested
from nulliparous (right panel) and parous (left panel) CAGMYC female mice treated with DOX for 5 days (DD5). Scale: 200 µm. n= 7 pre-pregnancy
mammary glands (left bar) and n= 6 post-pregnancy mammary glands (right bar). Bars indicate mean number of ducts. *p= 0.0001. c Western blot of
cMYC protein (62 kDa) in pre-pregnancy and post-pregnancy CAGMYC total MECs, with and without DOX treatment (5 days). GAPDH (146 kDa) used as
endogenous control. MM=molecular marker. d, e H&E-stained mammary glands images and duct quantification from nulliparous CAG-only control mice,
transplanted with pre-pregnancy and/or post-pregnancy CAGMYC CD1d+ MaSCs and treated with DOX for 5 days. Scale: 200 µm. n= 4 mammary
glands injected with pre-pregnancy CD1d+ MaSCs, and n= 4 mammary glands injected with post-pregnancy CD1d+ MaSCs. Bars indicate mean number
of total ducts (left) and abnormal ducts (right). n.s. not significant. *p= 0.003. f Immunofluorescence images of mammary glands from nulliparous CAG-
only control mice, transplanted with pre-pregnancy and post-pregnancy CAGMYC MaSCs and treated with DOX for 5 days, visualizing DAPI (blue), KRT8
(green), KRT5 (magenta), and cMYC (yellow). Scale: 100 µm. g H&E-stained mammary glands images from nulliparous CAG-only control mice,
transplanted with pre-pregnancy and/or post-pregnancy CAGMYC CD1d+ MaSCs and treated with DOX for 30 days. Scale: 500 µm. n= 4 mammary
glands injected with pre-pregnancy CD1d+ MaSCs, and n= 4 mammary glands injected with post-pregnancy CD1d+ MaSCs. h–j Representative images,
branching quantification, and size quantification of mammary organoid culture of pre- and post-pregnancy CAGMYC MECs, grown with essential media,
with or without DOX (0.5 μg/mL). Scale: 200 µm. n= 2 independent biological replicates and three technical replicates per experiment. i *p < 0.00001.
j n= 100 organoids, *p < 0.00001. For all analysis, error bars indicate standard error of mean across samples of same experimental group. p values were
defined using Student t test.
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of senescence-related genes, thus reverting their senescent state49.
To test the idea that post-pregnancy CAGMYC MECs can
autonomously resist perturbation by cMYC-driven oncogenic
programs in a p300/senescence-dependent manner, we treated
CAGMYC organoid cultures with small-molecule inhibitors that
block p300-histone acetyltransferase. Treatment of organoids
with the inhibitors PU139 and HATi resulted in a 2.6-fold and
2.4-fold increase in abnormal branching in post-pregnancy
CAGMYC organoid cultures, suggesting that inhibition of p300
increased adverse phenotypic changes in response to cMYC
overexpression (Fig. 4i and Supplementary Fig. 6j). These
alterations were not dependent on blocking cMYC activity, given
that pre-pregnancy CAGMYC organoids remained 2.9-fold larger
than organoids derived from CAGMYC post-pregnancy MECs,
after treatment with cMYC inhibitor (cMYCi) (Fig. 4j and
Supplementary Fig. 6k), thus supporting that specific perturba-
tions to post-pregnancy CAGMYC MECs can revert their ability
to respond to cMYC overexpression, and engage on malignant
transformation.
Discussion
Our results revealed epigenetic alterations to the MEC regulatory
landscape that enable reactivation of pregnancy-induced pro-
grams in response to pregnancy hormones. These programs
influenced the development of premalignant lesions in response
to oncogene overexpression. Our epigenetic and transcriptomic
analyses corroborate histological and cellular data, in both
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mammary gland tissue and organoid systems. These findings
demonstrate that cell autonomous signals present in post-
pregnancy MECs regulate gene expression, cellular activation,
and resistance to malignant transformation.
Previous studies of rodent and human post-pregnancy MECs
revealed parity-modulated factors and signaling networks that
may contribute to breast cancer risk11,50,51. Here, we have used a
similar approach, but have instead focused on the active, reg-
ulatory, epigenetic landscape of pre- and post-pregnancy murine
MECs, with the goal of understanding its role in transcriptional
activation, not only in response to signals from consecutive
pregnancies but also during the initial stages of oncogenesis.
Considering the possibility that not all malignant lesions may
progress into fully developed tumors, our findings suggest that
systems that suppress cancer development may be engaged in
post-pregnancy MECs, and block cancer initiation.
Interestingly, the expansion of the pregnancy-induced enhan-
cer landscape minimally recapitulated the transcriptional output
of post-pregnancy MECs during tissue homeostasis (non-preg-
nancy state), as demonstrated by our gene expression analyses
(Fig. 1). Thus, the chromatin state we assayed, the H3K27ac
activation mark, may not be sufficient to discriminate between
enhancer regions that were once highly active (during preg-
nancy), and those that acquired a less active/resting state after
parity, poised to respond to future pregnancy signals. It is also
possible that the abundance of specific TFs and the activity of
epigenetic factors fluctuate across non-pregnancy, pregnancy, and
post-pregnancy states, guiding additional chromatin remodeling
and gene expression control. Given it is less clear how post-
pregnancy cells reorganize their epigenome, we have focused our
analyses on the dynamics of enhancer activation and gene reg-
ulation in response to pregnancy and the early stages of onco-
genesis, revealing the complexity of the networks involved in
these events.
Our epigenomic and transcriptomic analyses utilized a cell
isolation strategy previously applied to isolate-defined MEC
populations12,27. However, we cannot exclude that, after preg-
nancy, these cell-surface markers recognize a more diverse cell
population compared with those existing prior to pregnancy.
Previous studies have reported parity-induced MECs5,52,53, and
recent single-cell RNA-seq analyses demonstrated alterations to
MEC populations throughout gestation, lactation, and involution
stages of mammary gland development54. However, DNA
methylation analyses of several mammary cell types from fully
involuted, post-pregnancy mammary glands have demonstrated
that alterations to the epigenome were, to some extent, shared by
most mammary cell types12, suggesting that pregnancy-induced
epigenomic alterations may not be restricted to MEC lineage
identities.
Our present study also revealed the relationship between cMYC
overexpression, pregnancy-induced epigenomic alterations, and
tissue/cellular abnormalities. cMYC, a potent oncogene, is over-
expressed in ~50% of human breast cancers55. In addition, several
oncogenic signaling networks (Brca1 loss, MAPK-Ras hyper-
activation, PI3K-AKT/PKB hyperactivation) converge on the
oncogenic potential of deregulated cMYC expression56. Further-
more, chromosomal abnormalities found in cMYC overexpressing
mouse models are syntenically and developmentally comparable
to those of human breast cancer57. Therefore, an inducible cMYC
overexpression model system to understand mammary malignant
initiation may help identify molecular targets for validation in
human breast specimens, improving understanding of mammary
oncogenesis.
It is important to note that signals driving early oncogenesis
may differ from those present after disease establishment. Our
analysis of pre-pregnancy CAGMYC MECs suggests that tran-
scriptional programs and the epigenome are differentially regu-
lated across the cMYC overexpression timeline, supporting the
notion that longer exposure to cMYC overexpression may
reprogram breast epithelial cellular identity58. Nonetheless, we
have shown that cMYC-driven signals do not fully induce epi-
genomic and transcriptomic alterations that support malignant
transformation of post-pregnancy mammary glands. This is also
seen in transplantation assays, where cMYC overexpressing post-
pregnancy CAGMYC MECs did not progress into malignant
transformation.
But how can pregnancy decrease mammary oncogenesis?
Previous studies established that both a full pregnancy cycle, and
an induced pseudo-pregnancy decreased the frequency of mam-
mary tumors in several mouse strains, including in chemically
induced mammary tumorigenesis models17,21, and those
accompanied by MMTV-driven cMYC overexpression22. Con-
versely, lack of active p53 is associated with the development of
mammary tumors in murine20,59 and human association stu-
dies60, suggesting that a decrease in p53 dosage in post-pregnancy
MECs may promote cancer initiation. Our study revealed a
substantial increase of p53 protein in post-pregnancy CAGMYC
organoids, possibly promoting a senescent state that could block
the development of malignant phenotypes.
It is also possible that pregnancy may induce alterations that
influence the mammary gland stroma and/or its immune com-
position. Pregnancy-induced alterations to the mammary gland
Fig. 4 Post-pregnancy MECs have limited response to cMYC overexpression. a Gene expression hierarchical clustering of DOX-treated (DD5), FACS-
isolated, pre- and post-pregnancy CAGMYC MECs. b GSEA analysis of gene networks downregulated in DOX-treated, FACS-isolated, pre- and post-
pregnancy CAGMYC MECs. NES normalized enrichment score. c, d Averaged H3K27ac intensity at (c) promoter regions or (d) parity-induced elements
(PIEs) of FACS-isolated, pre- and post-pregnancy WT and CAGMYC MECs (DD5). Error bars represent the variation of H3K27ac intensity at analyzed
regions. Center line represents the median of the dataset. Bounds of the box represent the 25th (lower bound) and 75th percentile (upper bound).
Whiskers represent the minimum and maximum of the non-outlier data. e Density plot showing computationally defined e-box DNA binding motifs with
high ATAC-seq peak intensity in pre-pregnancy CAGMYC (DD5), compared with ATAC-seq peak intensity at same e-box DNA binding site in post-
pregnancy CAGMYC MECs (DD5). f cMYC Cut&Run peak enrichment analysis, showing peaks enriched (red) or depleted (blue) in post-pregnancy
CAGMYC MECs (DD5). p value= 0.05 or lower. g Genome browser tracks showing cMYC occupancy in DOX-treated, pre- and post-pregnancy
CAGMYC MECs. h Western blot of cMYC, p300, and acethyl-p300 proteins in organoid cultures derived from pre-pregnancy and post-pregnancy
CAGMYC MECs, with and without DOX treatment (2 days). Vinculin protein levels were used as endogenous control. MM=molecular marker. i Number
of branched organoids from pre- and post-pregnancy CAGMYC MECs organoid cultures, grown with essential media and DOX (2 days, 0.5 μg/mL), with
and without histone acetyltransferase inhibitors (HATi =HAT Inhibitor II 10 μM and PU139 20 μM). n= 30 organoids, *p= 0.0001; n.s.= no statistically
significant differences. j Size quantification of pre- and post-pregnancy CAGMYC mammary organoids, grown with essential media and DOX (5 days, 0.5
mg/mL), with and without cMYC inhibitor (cMYCi = cMyc inhibitor (10058-F4) 10 μM). n= 30 organoids, *p= 0.0006; **p= 0.002. For all analysis,
error bars indicate standard error of mean across samples of same experimental group. p values were defined using Student t test.
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ECM have been suggested to play a role in preventing the pro-
gression of established cancer cells61–63. Alterations to immune
composition during post-pregnancy mammary gland involution
have also been suggested to influence mammary tumor progres-
sion64. Interactions among the stroma, immune system and the
MEC epigenome should be explored to define their roles in
blocking the early onset of oncogenesis in a post-pregnancy set-
ting, and to reveal their intersection with the parity-induced
epigenomic changes we describe.
Importantly, our mammary organoid experiments confirmed
the cell-autonomous characteristics of pregnancy-induced chan-
ges, and their ability to block responses to cMYC overexpression.
Using this system, we confirmed post-pregnancy MECs are less
responsive to cMYC overexpression. Our analysis also demon-
strated the utility of the organoid system for perturbing signals
present in post-pregnancy MECs. Utilizing combinations of
small-molecule inhibitors and genetic manipulations in this sys-
tem will enable the identification of signals that either promote or
block responses to oncogenic signals in a target-specific manner.
Finally, our data revealed the stability of the pregnancy-
induced epigenome, both in in vivo and in vitro pregnancy-naïve
environments, emphasizing the cell-autonomous nature of the
altered post-pregnancy epigenome. Such in vivo and in vitro
strategies will be required to monitor the dynamics of enhancer
activity and transcriptional regulation in a pregnancy-hormone
dependent fashion. Ultimately, the use of in vitro organoid stra-
tegies may allow for better understanding of enhancer activation,
transcriptional regulation, and responses to oncogenes in breast
tissue obtained from women with various reproductive histories,
with the goal to identify and characterize the human-specific
features of pregnancy-induced developmental dynamics in cancer
predisposition.
Methods
Mouse lines. Balb/C and C57/BL6 female mice were purchased from Charles
River. CAGs-rtTA3 mice (B6N.FVB(Cg)-Tg(CAG-rtTA3)4288Slowe/J, the Jackson
Laboratory) and tetO-MYC mice (FVB/N-Tg(tetO-MYC)36aBop/J, the Jackson
Laboratory) were crossed for the establishment of CAGMYC transgenic mouse
strain (129/C57BL6 background). All animals were housed at a 12 light/12 dark
cycle, with a controlled temperature of 72 °F and 40–60% of humidity. All
experiments were performed in agreement with approved CSHL Institutional
Animal Care and Use Committee.
Mammary gland isolation. Mammary glands were harvested and processed as
fully described in “Supplementary Methods.” In short, mammary glands were
harvested and digested into a single-cell suspension. MECs were separated from
immune cells (CD45+), red blood cells (TER119+), endothelial cells (CD31+),
and fibroblasts (CD34+) using lineage depletion antibodies and MACS magnetic
column (Miltenyi Biotech). Lineage-depleted (LIN−) MECs were utilized as
described in “Supplementary Methods.”
Illumina library preparation and NextGen sequencing. FACS-isolated MECs
were utilized for the preparation of NextGen Illumina libraries, as described in
“Supplementary Methods.”
Histological analysis. Tissue histology and immunofluorescence staining (IF)
were performed as described in “Supplementary Methods.”
Reporting summary. Further information on research design is available in
the Reporting Summary linked to this article.
Data availability
All data publicly accessible through NCBI databases [https://www.ncbi.nlm.nih.gov/].
RNA-seq, ChIP-seq, ATAC-seq, and Cut&Run datasets are available in the BioProject
database under number PRJNA544746 [https://www.ncbi.nlm.nih.gov/bioproject/
PRJNA544746]. Results described on Fig. 1a, b, prepregnancy MECs RNA-seq are found
in the BioProject database under number PRJNA192515 [https://www.ncbi.nlm.nih.gov/
bioproject/?term=PRJNA192515]. Results described on Fig. 2d, a total of 157 mammary
tumor tissue samples can be retrieved within the GEO Profiles database under numbers
GSE13221 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13221], GSE15904
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15904], and GSE30805
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30805].
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